Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Precursor cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    109 result(s) found for: Precursor cells. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2016-002739-14 Sponsor Protocol Number: ACT14596 Start Date*: 2016-12-07
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients with Relapsed or Refractory T-acute Lymphoblastic Leukemia ...
    Medical condition: Haematological malignancy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042987 T-cell type acute leukaemia PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036543 Precursor T-lymphoblastic lymphoma/leukaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000999-26 Sponsor Protocol Number: 13-006 Start Date*: 2014-09-20
    Sponsor Name:Jazz Pharmaceuticals, Inc.
    Full Title: An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (asparaginase Erwinia chrysanthemi)/Erwinase® (crisantaspase) Administered Following Hypersensitivity to E. c...
    Medical condition: 1) Acute Lymphoblastic Leukemia 2) Lymphoblastic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004851 10036544 Precursor T-lymphoblastic lymphomas/leukaemias HLT
    17.0 100000004851 10036524 Precursor B-lymphoblastic lymphomas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001861-17 Sponsor Protocol Number: Start Date*: 2004-12-12
    Sponsor Name:NOPHO-NHL GRUPP
    Full Title: EURO-LB-02. Treatment Protocol for Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL).
    Medical condition: Multicenter randomised trial conducted in european countries and the five nordic countries on children up to the age of 18 years newly diagnosed with T-cell and and pre -B lymphoblastic lymphoma (T...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Temporarily Halted) NO (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002333-42 Sponsor Protocol Number: OC-01-21001 Start Date*: 2022-11-25
    Sponsor Name:OneChain Immunotherapeutics
    Full Title: Safety and efficacy of hCD1a-CAR T (OC-1) therapy, in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)
    Medical condition: Children older than 2 years or adults, male and female, with refractory or relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma (T-ALL/LL).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036546 Precursor T-lymphoblastic lymphoma/leukaemia recurrent PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020497-41 Sponsor Protocol Number: ANG.AMI-IC001 Start Date*: 2013-02-13
    Sponsor Name:Mesoblast, Inc.
    Full Title: A prospective, double blind, randomized, placebo-controlled clinical trial of intracoronary infusion of immunoselected, bone marrow-derived Stro3 mesenchymal precursor cells (MPC) in the treatment ...
    Medical condition: ST-elevation myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) DK (Completed) SE (Completed) CZ (Completed) AT (Prematurely Ended) PL (Completed) IT (Prematurely Ended) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005674-61 Sponsor Protocol Number: MSB-RA002 Start Date*: 2013-09-11
    Sponsor Name:Mesoblast, Inc
    Full Title: A double-blind, randomized, placebo-controlled, multi-center, dose escalation study of a single intravenous infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in the treatment of biologic-na...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) EE (Prematurely Ended) LV (Completed)
    Trial results: View results
    EudraCT Number: 2004-004286-15 Sponsor Protocol Number: BCX1777-T-04-201 Start Date*: 2005-04-12
    Sponsor Name:BioCryst Pharmaceuticals Inc.
    Full Title: A Phase II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with Advanced T-Cell Leukemia with an Option of Long-Term Forodesine Hydrochloride Use
    Medical condition: Advanced T-cell Leukaemia (either precursor T-Lymphoblastic Leukaemia/Lymphoma or T-cell Prolymphocytic Leukaemia [T-PLL]).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10024324 hlgt
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000766-30 Sponsor Protocol Number: HO146 Start Date*: 2018-03-09
    Sponsor Name:HOVON Foundation
    Full Title: Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. A phase II trial.
    Medical condition: Precursor B-acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002476-92 Sponsor Protocol Number: 20120215 Start Date*: 2015-06-29
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open-label, Controlled Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidatio...
    Medical condition: Patients with Philadelphia chromosome negative (Ph-) high-risk (HR) first relapse B-precursor ALL (as defined by I-BFM SG/IntReALL criteria)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    21.1 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BE (Completed) IT (Completed) SE (Completed) PT (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) FR (Completed) NL (Completed) Outside EU/EEA GR (Completed) NO (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-005010-30 Sponsor Protocol Number: KTE-C19-104 Start Date*: 2017-09-27
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)
    Medical condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) SE (Completed) BE (Completed) PL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002314-31 Sponsor Protocol Number: DLI-TARGET Start Date*: 2018-08-20
    Sponsor Name:Klinikum der Universität München
    Full Title: Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined with Blinatumomab in Patients with Treatment-Resistant Mixed Chimerism or Minimal Re...
    Medical condition: Subjects with treatment-resistant mixed chimerism or MRD of CD19+ B-precursor ALL after allogeneic SCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10063621 Acute lymphoblastic leukaemia recurrent LLT
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004324-14 Sponsor Protocol Number: WU-CART-007-1001 Start Date*: 2023-06-26
    Sponsor Name:Wugen, Inc.
    Full Title: A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic L...
    Medical condition: Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042987 T-cell type acute leukaemia PT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006520-19 Sponsor Protocol Number: MT103-202 Start Date*: 2007-10-11
    Sponsor Name:Amgen Research (Munich) GmbH
    Full Title: An open-label, multicenter phase II study to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BITE) MT103 in patients with minimal residual disease (MRD) of pos...
    Medical condition: Patients with minimal residual disease (MRD) of positive B-precursor acute lymphoblastic leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018314-75 Sponsor Protocol Number: MT103-203 Start Date*: 2010-08-05
    Sponsor Name:Amgen Research (Munich) GmbH
    Full Title: A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor...
    Medical condition: minimal residual disease (MRD) of B-precursor ALL
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004942-27 Sponsor Protocol Number: P16/11 Start Date*: 2017-07-17
    Sponsor Name:Centre Hospitalier de Versailles
    Full Title: A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients with Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia
    Medical condition: Philadelphia chromosome (Ph)-negative CD22+ B-cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012958 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005009-35 Sponsor Protocol Number: KTE-C19-103 Start Date*: 2018-09-25
    Sponsor Name:Kite Pharma Inc.
    Full Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)
    Medical condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003038-17 Sponsor Protocol Number: CART19-BE-02 Start Date*: 2020-09-18
    Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
    Full Title: Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity...
    Medical condition: CD19+ acute lymphoid leukemia resistant or refractory to treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10060555 Acute lymphoid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003409-23 Sponsor Protocol Number: MERMAID1 Start Date*: 2023-12-12
    Sponsor Name:Medical University of Warsaw
    Full Title: Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease. Phase I/I...
    Medical condition: B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001697-17 Sponsor Protocol Number: R1979-ONC-1504 Start Date*: 2015-12-01
    Sponsor Name:Regeneron Pharmaceuticals, Inc
    Full Title: A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an anti-CD20 x anti- CD3 bispecific monoclonal antibody, and REGN2810, an anti-programmed death-1 monoclonal antibody, in Patients wit...
    Medical condition: B-cell malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003917 B-cell type acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026945 Mature B-cell type acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067184 Burkitt's leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003890 B precursor type acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2014-001673-14 Sponsor Protocol Number: CCTL019A2205B Start Date*: 2015-10-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
    Medical condition: All patients who have been treated with chimeric antigen receptor (CAR) T-cell therapy in the context of a prior Novartis sponsored or supported study for any indication.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003917 B-cell type acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 12 22:04:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA